Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of PepGen.

    Client Virtual Booth

    PEPGEN

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    PepGen
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    245 Main St, Cambridge, MA 02142
    Telephone
    Telephone
    +44 1865 618 820
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pepgen.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

    Details:

    PGN-EDO51 blocks the inclusion of exon 51, restoring functional, dystrophin production. Today it received U.S. FDA orphan drug and rare pediatric disease designations for the treatment of duchenne muscular dystrophy.


    Lead Product(s): PGN-EDO51

    Therapeutic Area: Genetic Disease Product Name: PGN-EDO51

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 13, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial Designed to ...

    Details:

    PGN-EDO51, PepGen’s lead clinical candidate for the treatment of DMD, utilizes the Enhanced Delivery Oligonucleotide (EDO) technology to deliver a therapeutic oligonucleotide. It is under phase 2 clinical development for the treatment of Duchenne Muscular Dystrophy.


    Lead Product(s): PGN-EDO51

    Therapeutic Area: Genetic Disease Product Name: PGN-EDO51

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 04, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

    Details:

    PGN-EDODM1 is an investigational candidate designed to deliver a peptide-conjugated antisense oligonucleotide (ASO) to restore cellular function. It is under development for the treatment of Myotonic Dystrophy Type 1.


    Lead Product(s): PGN-EDODM1

    Therapeutic Area: Genetic Disease Product Name: PGN-EDODM1

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 20, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock

    Details:

    The net proceeds will be used for the development of PGN-EDO51, which is designed to skip exon 51 of the dystrophin transcript for the treatment of Duchenne muscular dystrophy.


    Lead Product(s): PGN-EDO51

    Therapeutic Area: Genetic Disease Product Name: PGN-EDO51

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: RA Capital Management

    Deal Size: $80.1 million Upfront Cash: Undisclosed

    Deal Type: Public Offering February 07, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 ...

    Details:

    PGN-EDO51, PepGen’s lead clinical candidate for the treatment of DMD, utilizes the Enhanced Delivery Oligonucleotide (EDO) technology to deliver a therapeutic oligonucleotide. It is under phase 2 clinical development for the treatment of Duchenne Muscular Dystrophy.


    Lead Product(s): PGN-EDO51

    Therapeutic Area: Genetic Disease Product Name: PGN-EDO51

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

    Details:

    PGN-EDODM1 is an investigational candidate designed to deliver a peptide-conjugated antisense oligonucleotide (ASO) to restore cellular function. It is under phase 1 clinical development for the treatment of Myotonic Dystrophy Type 1.


    Lead Product(s): PGN-EDODM1

    Therapeutic Area: Genetic Disease Product Name: PGN-EDODM1

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myoto...

    Details:

    PGN-EDODM1 is an investigational candidate designed to deliver a peptide-conjugated antisense oligonucleotide (ASO) to restore cellular function, it is being investigated for the treatment of myotonic dystrophy type 1.


    Lead Product(s): PGN-EDODM1

    Therapeutic Area: Genetic Disease Product Name: PGN-EDODM1

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 12, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1

    Details:

    PGN-EDODM1, delivers a peptide conjugated antisense oligonucleotide (ASO) to restore cellular function, it is being investigated for the treatment of myotonic dystrophy type 1.


    Lead Product(s): PGN-EDODM1

    Therapeutic Area: Genetic Disease Product Name: PGN-EDODM1

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 06, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

    Details:

    PGN-EDODM1, delivers a peptide conjugated antisense oligonucleotide (ASO) to restore cellular function, it is being investigated for the treatment of myotonic dystrophy type 1.


    Lead Product(s): PGN-EDODM1

    Therapeutic Area: Genetic Disease Product Name: PGN-EDODM1

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 13, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

    Details:

    PGN-EDODM1, delivers a peptide conjugated antisense oligonucleotide (ASO) to restore cellular function, it is being investigated for the treatment of myotonic dystrophy type 1.


    Lead Product(s): PGN-EDODM1

    Therapeutic Area: Genetic Disease Product Name: PGN-EDODM1

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 30, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search